HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jose Jimenez Selected Research

Neoplasms (Cancer)

10/2023A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials.
10/2020Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.
1/2020Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials.
1/2019Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer.
4/2015PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
6/2014Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.
2/2012USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jose Jimenez Research Topics

Disease

7Neoplasms (Cancer)
10/2023 - 02/2012
4Colorectal Neoplasms (Colorectal Cancer)
12/2022 - 09/2011
3Breast Neoplasms (Breast Cancer)
06/2022 - 04/2015
2Congenital Abnormalities (Deformity)
10/2023 - 10/2023
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 01/2021
2Prostatic Neoplasms (Prostate Cancer)
01/2018 - 01/2017
2Adenocarcinoma
06/2014 - 09/2011
1Nausea
10/2023
1Microsatellite Instability
12/2022
1Pathologic Complete Response
04/2015
1Adenocarcinoma of Lung
06/2014
1Head and Neck Neoplasms (Head and Neck Cancer)
06/2014
1Colonic Neoplasms (Colon Cancer)
06/2014
1Lung Neoplasms (Lung Cancer)
06/2014
1Glioblastoma (Glioblastoma Multiforme)
02/2012
1Carcinogenesis
09/2011
1Infections
01/2011

Drug/Important Bio-Agent (IBA)

3Biomarkers (Surrogate Marker)IBA
12/2022 - 01/2019
3Proteins (Proteins, Gene)FDA Link
01/2019 - 01/2011
2Parathyroid Hormone (Parathormone)IBA
10/2023 - 10/2023
2Immune Checkpoint InhibitorsIBA
01/2022 - 01/2021
2PolyaminesIBA
01/2018 - 01/2017
2ErbB Receptors (EGF Receptor)IBA
04/2015 - 06/2014
1Hormones (Hormone)IBA
06/2022
1B7-H1 AntigenIBA
01/2022
1Keratins (Keratin)IBA
10/2020
1Formaldehyde (Formol)FDA Link
01/2020
1ParaffinIBA
01/2020
1Thymidine Monophosphate (TMP)IBA
01/2019
1Mechanistic Target of Rapamycin Complex 1IBA
01/2017
1S-adenosyl-3-methylthiopropylamineIBA
01/2017
1Trastuzumab (Herceptin)FDA Link
04/2015
1human ERBB2 proteinIBA
04/2015
1Lapatinib (GW572016)FDA Link
04/2015
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
04/2015
1Phosphotransferases (Kinase)IBA
06/2014
1AntibodiesIBA
06/2014
1Cetuximab (Erbitux)FDA Link
06/2014
1Transforming Growth Factors (Transforming Growth Factor)IBA
02/2012
1CateninsIBA
09/2011

Therapy/Procedure

4Immunotherapy
10/2023 - 01/2020
4Therapeutics
10/2023 - 06/2014
1Neoadjuvant Therapy
04/2015